Core Viewpoint - China Tongru (01763) experienced a significant stock increase of over 10%, reaching HKD 20.94 with a trading volume of HKD 24.42 million, following the launch of its carbon isotope product and the second phase of its stable isotope base project in Tongcheng, Anhui on October 31 [1] Group 1: Project Launch and Production Capacity - The newly launched project is expected to produce 2,000 kilograms of high-abundance 13CO gas and 4,000 kilograms of 13C urea raw materials annually, along with other raw materials for gastrointestinal disease treatment drugs [1] - The high-abundance 13CO gas is a critical raw material used in the urea breath test for detecting Helicobacter pylori infections [1] Group 2: Market Impact and Self-Sufficiency - The launch of high-abundance 13CO gas and urea products signifies China's break from long-term reliance on imports for the 13CO gas used in urea breath diagnostics [1] - This development allows China to achieve a fully self-controlled industrial chain in the medical stable isotope carbon sector, from key raw materials to end products, thereby establishing a solid foundation for a safe and reliable high-end medical isotope supply chain [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國同輻股份有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01763 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 79,968,800 | RMB | | 1 | RMB | | 79,968,800 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 79,968,800 | RMB | | 1 | RMB | | 79,968,800 | | 2. 股份分類 ...

Core Viewpoint - China Tongru (01763) experienced a significant stock price increase of over 7% during trading, attributed to the launch of high-purity 13CO gas and urea products, marking a shift towards self-sufficiency in the medical stable isotope carbon sector [1] Company Overview - China Tongru is a specialized company under China National Nuclear Corporation, focusing on nuclear technology applications, including the development, production, and sales of nuclear medicine, radiation source products, and related services [1] - The company has established a comprehensive layout in the nuclear medicine field, with a network of 37 medical centers and 7 R&D production bases by December 31, 2024, positioning itself as a leader in China's nuclear medicine sector [1] Industry Impact - The launch of high-purity 13CO gas and urea products signifies China's ability to break free from reliance on imported materials for urea breath diagnostic agents, achieving full control over the entire industry chain from key raw materials to end products [1] - This development enhances the company's status as a leading enterprise capable of managing the complete supply chain for breath test products in the medical stable isotope carbon field [1]

Core Viewpoint - China Tongru (01763) experienced a significant stock price increase, rising over 7% during trading and closing at 20.16 HKD, with a transaction volume of 10.36 million HKD, following the launch of its high-abundance 13CO gas and urea products, marking a milestone in the domestic production of medical stable isotopes [1] Company Overview - China Tongru is a specialized company under the China National Nuclear Corporation, focusing on nuclear technology applications, including the development, production, sales, and services related to nuclear medicine, radiation source products, and nuclear medical equipment [1] - The company has established a comprehensive layout in the nuclear medicine sector, with a network of 37 medical centers and 7 R&D production bases by December 31, 2024, positioning itself as a leading enterprise in China's nuclear medicine field [1] Industry Impact - The successful launch of the high-abundance 13CO gas and urea products signifies China's achievement in breaking the long-standing reliance on imports for the raw materials used in urea breath diagnostic tests, enabling full domestic control over the entire industry chain from key raw materials to end products [1] - This development positions China Tongru as a leading enterprise that fully masters the entire industry chain of breath test products, enhancing its competitive edge in the medical stable isotope market [1]

Core Viewpoint - The launch of the stable isotope base phase II project by China Tongfu marks a significant advancement in the domestic production of high-abundance 13CO gas and 13C urea raw materials, reducing reliance on imports and establishing a comprehensive domestic supply chain for medical stable isotopes [1] Group 1 - The project, initiated on October 31, aims to produce 2000 kilograms of high-abundance 13CO gas and 4000 kilograms of 13C urea raw materials annually [1] - High-abundance 13CO gas is a critical raw material used in the urea breath test for detecting Helicobacter pylori infections [1] - The launch signifies China's achievement in establishing a fully autonomous and controllable supply chain in the medical stable isotope carbon sector, from key raw materials to end products [1]

Core Viewpoint - China Tongru (01763) has made a significant breakthrough in the field of stable isotopes by launching carbon isotope products, marking China's advancement in high-end technology and reducing reliance on imports for key medical materials [1] Group 1: Product Launch and Significance - The launch of high-abundance 13CO gas and carbon-13 urea raw materials positions China as one of the few countries capable of producing these essential components for medical applications [1] - The new products will eliminate China's complete dependence on imports for 13CO used in urea breath tests for detecting Helicobacter pylori infections, enhancing domestic production capabilities [1] Group 2: Industry Impact and Future Projects - The announcement coincides with the initiation of the second phase of the stable isotope base project, which will ensure a stable supply of high-abundance 13CO gas and other raw materials for gastrointestinal disease treatments [1] - This development is expected to significantly contribute to national health improvement and the high-quality development of medical isotopes, aligning with the "Healthy China" initiative [1]

Core Viewpoint - China Tongfu (01763) has made a significant breakthrough in the stable isotope field by launching carbon isotope products, positioning China among the few countries capable of producing high-abundance CO gas and carbon-13 urea raw materials [1] Company Summary - The launch of high-abundance CO gas, a key raw material for urea breath tests used to detect Helicobacter pylori infections, marks the end of China's complete reliance on imports for this material [1] - China Tongfu has enhanced its research and production capabilities in stable isotope products, establishing itself as a leading enterprise with a complete grasp of the entire industrial chain for breath test products [1] Industry Summary - The initiation of the second phase of the stable isotope base project will enable China Tongfu to ensure a stable supply of high-abundance CO gas, carbon-13 urea raw materials, and other raw materials for gastrointestinal disease treatment [1] - This development is expected to significantly contribute to improving national health standards, promoting high-quality development of medical isotopes, and supporting the "Healthy China" initiative [1]

Core Viewpoint - China Tongru (01763.HK) has announced the launch of carbon isotope products, marking a significant breakthrough in high-end technology in the stable isotope field, making China one of the few countries capable of producing high-abundance 13CO gas and carbon-13 urea raw materials for pharmaceuticals [1] Group 1: Product Launch and Significance - The release of high-abundance 13CO gas is crucial for the urea breath test used to detect Helicobacter pylori infection, indicating a shift from complete reliance on imports for this material [1] - This product launch significantly enhances China's research and production capabilities in stable isotope products, positioning China Tongru as a leading enterprise with a complete grasp of the entire industrial chain for breath test products [1] Group 2: Future Developments - On the same day, China Tongru officially commenced the construction of the second phase of its stable isotope base project, which will establish a stable supply capability for high-abundance 13CO gas, carbon-13 urea raw materials, and other raw materials for gastrointestinal disease treatment drugs [1] - The completion of this project is expected to contribute to improving national health levels, promoting high-quality development of medical isotopes, and supporting the "Healthy China" initiative [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 1 當日，中國同輻正式啟動穩定同位素基地二期項目建設，項目建成後，中國同輻 將形成高豐度13CO氣體、碳13尿素原料藥以及其它覆蓋胃腸道疾病治療藥物原 料藥的穩定供應能力，對提升國民健康水平、促進醫用同位素高質量發展、服務 「健康中國」建設具有重要意義。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年10月31日 自願性公告 中國同輻突破呼氣診斷關鍵原料技術 成為完整掌握呼氣試驗產品全產業鏈的龍頭企業 本公告乃中國同輻股份有限公司（「中國同輻」或「本公司」）自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 本公司董事會（「董事會」）欣然宣佈，10月31日，中國同輻發佈碳同位素產品，標 誌着我國在穩定同位素領 ...

Core Viewpoint - The company, 原子高科, has been recognized as a national-level "specialized, refined, and innovative" small giant enterprise, highlighting its innovation and expertise in nuclear technology applications [1] Group 1: Recognition and Standards - 原子高科 has been included in the national-level list of specialized and innovative small giant enterprises, which is a recognition of its capabilities in the field of radioactive isotope technology [1] - The evaluation criteria for this recognition include business focus, R&D investment intensity, innovation capability, and market share, indicating that 原子高科 excels in these core dimensions [1] Group 2: Implications and Future Directions - This recognition marks 原子高科's entry into the national key cultivation tier, providing an opportunity for the company to enhance its core competitiveness [1] - The company aims to uphold and promote the spirit of craftsmanship, focusing on technological innovation driven by market demand to contribute more to human health [1]